Nektar Therapeutics (STU:ITH0) Cyclically Adjusted Book per Share: €55.32 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ITH0 Nektar Therapeutics STU:ITH0
52 GF Score
Price €57.48
GF Value €4.62
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Cyclically Adjusted Book per Share?

Nektar Therapeutics STU:ITH0 -2.74% 52 Cyclically Adjusted Book per Share is €55.32 as of Jun. 2026. GuruFocus rates STU:ITH0 with a GF Score™ of 52/100 and a GF Value™ of €4.62 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was €23.145. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €55.32 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Book Growth Rate was 5.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nektar Therapeutics was 49.10% per year. The lowest was -26.40% per year. And the median was 1.30% per year.

As of today (2026-09-16), Nektar Therapeutics's current stock price is €57.48. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €55.32. Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is 1.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.33.


Nektar Therapeutics  (STU:ITH0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=57.48/55.319
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.33.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nektar Therapeutics Cyclically Adjusted Book per Share Related Terms


Nektar Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Cyclically Adjusted Book per Share Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.40 45.15 48.69 50.11 51.74

Nektar Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.11 52.43 52.39 54.00 55.32

STU:ITH0 vs PHVS, PGEN, VERA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:ITH0
52GF Score
Nektar Therapeutics STU:ITH0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=23.145/333.9520*333.9520
=23.145

Current CPI (Jun. 2026) = 333.9520.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -6.573 241.428 -9.092
201612 8.180 241.432 11.315
201703 4.056 243.801 5.556
201706 0.286 244.955 0.390
201709 6.804 246.819 9.206
201712 6.877 246.524 9.316
201803 4.378 249.554 5.859
201806 138.628 251.989 183.719
201809 133.587 252.439 176.722
201812 129.876 251.233 172.638
201903 125.249 254.202 164.543
201906 117.225 256.143 152.835
201909 116.523 256.759 151.555
201912 106.401 256.974 138.274
202003 99.643 258.115 128.919
202006 93.828 257.797 121.545
202009 83.496 260.280 107.129
202012 73.335 260.474 94.022
202103 69.629 264.877 87.787
202106 62.287 271.696 76.559
202109 56.212 274.310 68.434
202112 48.326 278.802 57.885
202203 43.995 287.504 51.103
202206 35.121 296.311 39.582
202209 33.582 296.808 37.785
202212 27.328 296.797 30.749
202303 17.573 301.836 19.443
202306 14.243 305.109 15.589
202309 11.835 307.789 12.841
202312 9.294 306.746 10.118
202403 9.584 312.332 10.247
202406 6.059 314.175 6.440
202409 3.562 315.301 3.773
202412 4.736 315.605 5.011
202503 1.025 319.799 1.070
202506 -1.656 322.561 -1.714
202509 3.685 324.800 3.789
202512 3.753 324.054 3.868
202603 24.540 330.213 24.818
202606 23.145 333.952 23.145

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €55.32 mean?
Nektar Therapeutics (STU:ITH0) has a Cyclically Adjusted Book per Share of €55.32 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Cyclically Adjusted Book per Share too high?
Nektar Therapeutics' current Cyclically Adjusted Book per Share is €55.32. Overall, Nektar Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Cyclically Adjusted Book per Share compare to PHVS and PGEN?
Nektar Therapeutics' Cyclically Adjusted Book per Share of €55.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Cyclically Adjusted Book per Share is €55.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (STU:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.62, compared to a current price of €57.48 — trading 1144.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is €55.32. Nektar Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Nektar Therapeutics (STU:ITH0), the current Cyclically Adjusted Book per Share is €55.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (STU:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €57.48 is trading 1144.2% above its estimated GF Value™ of €4.62. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:ITH0:

  • Cyclically Adjusted Book per Share: €55.32
  • GF Value™: €4.62 vs. price of €57.48 (1144.2% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the STU:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UK
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
52GF Score

Get the complete analysis for STU:ITH0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€57.48
Price
€4.62
GF Value